PRESS RELEASE: Jacobs Receives Contract from Pfizer for New Biotech Manufacturing Center in Ireland

Jacobs Receives Contract from Pfizer for New Biotech Manufacturing Center in Ireland

PASADENA, Calif., Aug. 14 -- Jacobs Engineering Group announced today that it received a contract from Pfizer Limited to provide construction management services for a new small-scale clinical biotech manufacturing center in Shanbally, Cork, Ireland.

Officials did not disclose the value of the contract.

This will be the first such facility built on Pfizer's 28-acre brownfield site at Shanbally. The facility will accommodate a production plant, laboratories, administration, and associated infrastructure. Jacobs will start construction in September 2007, with manufacturing scheduled to start in the completed facility by late 2009. Jacobs will manage all work from its offices in Cork.

In making the announcement, Jacobs Group Vice President Phil Stassi stated, "This planned facility is an important milestone in Pfizer's investment strategy for the Shanbally site and we are pleased to support it. Jacobs has worked successfully with Pfizer around the world and we are enthusiastic about this opportunity to build further on our joint relationship."

Jacobs, with over 48,000 employees and revenues exceeding $8.0 billion, provides technical, professional, and construction services globally.

Any statements made in this release that are not based on historical fact are forward-looking statements. Although such statements are based on management's current estimates and expectations, and currently available competitive, financial, and economic data, forward-looking statements are inherently uncertain. We, therefore, caution the reader that there are a variety of factors that could cause business conditions and results to differ materially from what is contained in our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2006 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We also caution the readers of this release that we do not undertake to update any forward-looking statements made herein.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.